UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Responsible scientific research at Inserm: a field study

International journal of metrology and quality engineering, 2020, Vol.11, p.1

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Binding of Raltegravir to Plasma Proteins

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.5147-5150

2013

Link zum Volltext

Verfügbarkeit prüfen

Stimulation of HIV-Specific Cellular Immunity by Structured Treatment Interruption Fails to Enhance Viral Control in Chronic HIV Infection

Proceedings of the National Academy of Sciences - PNAS, 2002-10, Vol.99 (21), p.13747-13752

2002

Link zum Volltext

Verfügbarkeit prüfen

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

Antimicrobial Agents and Chemotherapy, 2013-02, Vol.57 (2), p.758-765

2013

Link zum Volltext

Verfügbarkeit prüfen

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

AIDS (London), 2004-09, Vol.18 (14), p.1951-1953

2004

Link zum Volltext

Verfügbarkeit prüfen

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial)

PloS one, 2013-01, Vol.8 (1), p.e53621-e53621

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy

Clinical infectious diseases, 2015-10, Vol.61 (8), p.1328-1335

2015

Link zum Volltext

Verfügbarkeit prüfen

Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)

Clinical infectious diseases, 2022-11, Vol.75 (10), p.1868-1871

2022

Link zum Volltext

Verfügbarkeit prüfen

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response

Journal of antimicrobial chemotherapy, 2015-07, Vol.70 (7), p.2090-2096

2015

Link zum Volltext

Verfügbarkeit prüfen

Tropism distribution among antiretroviral-naive HIV-2-infected patients

AIDS (London), 2015-10, Vol.29 (16), p.2209-2212

2015

Link zum Volltext

Verfügbarkeit prüfen

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression

Journal of antimicrobial chemotherapy, 2016-03, Vol.71 (3), p.751-761

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

Journal of acquired immune deficiency syndromes (1999), 2012-04, Vol.59 (5), p.489

2012

Link zum Volltext

Verfügbarkeit prüfen

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Journal of antimicrobial chemotherapy, 2018-06, Vol.73 (6), p.1672-1676

2018

Link zum Volltext

Verfügbarkeit prüfen

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

Journal of antimicrobial chemotherapy, 2017-01, Vol.72 (1), p.240-245

2017

Link zum Volltext

Verfügbarkeit prüfen

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients

AIDS (London), 2014-09, Vol.28 (14), p.2160-2162

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial

The lancet HIV, 2018-03, Vol.5 (3), p.e126-e135

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)

Journal of antimicrobial chemotherapy, 2016-02, Vol.71 (2), p.490

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)

Journal of antimicrobial chemotherapy, 2016-02, Vol.71 (2), p.490-496

2016

Link zum Volltext

Verfügbarkeit prüfen

HIV-2 X4 tropism is associated with lower CD4 super(+) cell count in treatment-experienced patients

AIDS (London), 2014-09, Vol.28 (14), p.2160-2162

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

AIDS (London), 2010-10, Vol.24 (16), p.2581-2583

2010

Link zum Volltext

Verfügbarkeit prüfen

Recent developments in clinical trial designs for HIV vaccine research

Human vaccines & immunotherapeutics, 2015-01, Vol.11 (4), p.1022-1029

2015

Link zum Volltext

Verfügbarkeit prüfen

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Journal of antimicrobial chemotherapy, 2009-06, Vol.63 (6), p.1251-1255

2009

Link zum Volltext

Verfügbarkeit prüfen

Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123—ETOILE)

Journal of antimicrobial chemotherapy, 2010-10, Vol.65 (10), p.2212-2214

2010

Link zum Volltext

Verfügbarkeit prüfen

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ ritonavir regimen

AIDS (London), 2010-11, Vol.24 (17), p.2651-2656

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(73)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Humans
(51)
Life Sciences & Biomedicine
(48)
Infectious Diseases
(32)
Biological And Medical Sciences
(30)
Female
(29)
Male
(27)
Adult
(26)
Medical Sciences
(26)
Hiv Infections - Drug Therapy
(23)
Immunology
(18)
Hiv Infections - Virology
(17)
Life Sciences
(17)
Virology
(17)
Cd4 Lymphocyte Count
(15)
Hiv
(15)
Hiv Infections - Immunology
(15)
Human Immunodeficiency Virus
(15)
Viral Load
(15)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Responsible scientific research at Inserm: a field study

Characterization of Binding of Raltegravir to Plasma Proteins

Stimulation of HIV-Specific Cellular Immunity by Structured Treatment Interruption Fails to Enhance Viral Control in Chronic HIV Infection

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial)

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy

Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response

Tropism distribution among antiretroviral-naive HIV-2-infected patients

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)

HIV-2 X4 tropism is associated with lower CD4 super(+) cell count in treatment-experienced patients

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

Recent developments in clinical trial designs for HIV vaccine research

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123—ETOILE)

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ ritonavir regimen

Suchergebnisse filtern